A 28-year-old woman with severe atopic dermatitis refractory to topical corticosteroids and calcineurin inhibitors presents with widespread erythema, lichenification, and excoriation. Before initiating systemic immunosuppressive therapy, which investigation is most appropriate to assess disease severity and guide treatment selection?

Explanation

## Assessment of Atopic Dermatitis Severity **Key Point:** Before initiating systemic therapy for severe atopic dermatitis, **objective severity scoring** (SCORAD or EASI) is essential to quantify disease burden, guide treatment escalation, and monitor response. ### Severity Scoring Systems | Scoring System | Components | Use in Clinical Practice | |---|---|---| | **SCORAD (Scoring Atopic Dermatitis)** | Extent (0–100), intensity (erythema, edema, excoriation, lichenification), subjective symptoms (pruritus, sleep loss) | Gold standard for severity assessment; used in clinical trials; ranges 0–103 | | **EASI (Eczema Area and Severity Index)** | Area affected (0–72) + severity (erythema, edema, excoriation, lichenification) (0–72); total 0–144 | Simpler, more practical; increasingly used in routine practice | | **IGA (Investigator's Global Assessment)** | Single 5-point scale (clear to severe) | Quick bedside assessment; less sensitive to change | **High-Yield:** SCORAD ≥50 or EASI ≥16 indicates **severe atopic dermatitis** warranting systemic therapy (cyclosporine, azathioprine, dupilumab, JAK inhibitors). ### Why Severity Scoring Guides Treatment 1. **Baseline documentation:** Establishes disease severity before systemic therapy 2. **Treatment selection:** Severe disease (SCORAD >50) justifies biologic agents (dupilumab) or systemic immunosuppressants 3. **Monitoring response:** Serial SCORAD/EASI scores track therapeutic efficacy 4. **Regulatory/trial requirements:** Severity indices are mandatory for clinical trial enrollment and insurance approval of biologics **Clinical Pearl:** A patient with widespread erythema and lichenification is clinically severe, but **quantitative scoring** provides objective documentation needed for systemic therapy initiation and follow-up. ### Why Other Investigations Are Supportive, Not Primary - **Serum albumin/LFTs:** Baseline labs before systemic immunosuppressants (to assess hepatic/renal function), but not for severity assessment - **CXR/TB screening:** Mandatory before cyclosporine or azathioprine (to exclude TB), but not for initial severity grading - **Skin culture:** Indicated if bacterial superinfection is suspected (honey-crusted lesions, purulent drainage), not for severity assessment **Mnemonic:** **SCORE** before **SYSTEMIC** — Use SCORAD/EASI to grade severity, then select systemic therapy accordingly.